Research programme: quinoline compounds - Active Biotech

Drug Profile

Research programme: quinoline compounds - Active Biotech

Alternative Names: Inhibition of S100A9 Interactions; ISI; S100A9 Inhibition by Low molecular weight Compounds; SILC

Latest Information Update: 22 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Active Biotech
  • Class Quinolines
  • Mechanism of Action Advanced glycosylation end-product receptor antagonists; Toll-like receptor 4 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Cancer

Most Recent Events

  • 16 Feb 2017 Active Biotech has patent protection for quinoline compounds in Europe
  • 11 Nov 2016 Active Biotech is seeking partners for its quinolone compound development programme (Active Biotech pipeline, November 2016)
  • 01 Jun 2015 Suspended - Preclinical for Cancer in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top